Trial Profile
In-hospital outcomes of Eptifibatide versus Abciximab in dialysis patients undergoing percutaneous coronary intervention
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2016
Price :
$35
*
At a glance
- Drugs Eptifibatide (Primary) ; Abciximab
- Indications Acute coronary syndromes; Coronary artery disease
- Focus Adverse reactions
- 10 Oct 2016 New trial record